Johns Hopkins Digital Twin Hearts Achieve 100% Arrhythmia-Free Rate in First FDA-Approved Clinical Trial
The TWIN-VT trial used personalized computational heart models to guide ventricular tachycardia ablation, with all 10 patients remaining arrhythmia-free after more than a year.
Overview
Researchers at Johns Hopkins University have published results from the first FDA-approved clinical trial using digital twin technology to guide cardiac ablation procedures. The TWIN-VT trial, published on April 1, 2026 in the New England Journal of Medicine, demonstrated that all 10 patients with ventricular tachycardia remained arrhythmia-free more than a year after undergoing procedures planned on personalized computational replicas of their hearts.
What Happened
The trial enrolled 10 patients who had experienced heart attacks and subsequently developed ventricular tachycardia, a potentially life-threatening condition involving abnormal heart rhythms. For each participant, the research team built a personalized digital twin of their heart using three-dimensional contrast-enhanced magnetic resonance imaging, according to News Medical.
These computational models simulated the electrophysiological behavior of each patient’s heart, identifying arrhythmia sources, forecasting recurrence risk, and generating an optimal ablation strategy. The predicted targets were then imported directly into the catheter navigation system used during the actual procedure, as reported by Medical Xpress.
Results
Immediately following the procedure, ventricular tachycardia was noninducible in all 10 patients, meaning physicians could not stimulate arrhythmias in any subject, according to News Medical. At a follow-up period exceeding one year, all 10 patients remained arrhythmia-free, representing a 100 percent long-term success rate.
By comparison, traditional catheter ablation for ventricular tachycardia typically achieves a long-term success rate of approximately 60 percent, according to Medical Xpress. Eight of the 10 patients in the TWIN-VT trial were able to completely discontinue anti-arrhythmia medications, while the remaining two reduced their doses.
How It Works
The digital twin approach differs from conventional ablation in that it allows physicians to exhaustively test treatment scenarios in a virtual environment before entering the operating room. Rather than relying solely on real-time electrical mapping during the procedure, the computational model identifies all potential arrhythmia sources, including those that may be invisible to clinical examination, as reported by News Medical.
Jonathan Chrispin, a cardiologist at Johns Hopkins and first author of the study, stated that the approach makes procedures “safer, shorter and more effective by targeting only the critical portions of the heart,” according to Medical Xpress.
What We Don’t Know
The TWIN-VT trial was a feasibility study with only 10 participants, and the results, while striking, need to be validated in larger, randomized controlled trials before digital twin-guided ablation could become a standard clinical tool. It remains unclear how the technology would perform across a broader patient population with varying degrees of cardiac scarring and comorbidities.
The cost and time required to build each patient’s digital twin model have not been publicly detailed, raising questions about scalability. Access to the specialized MRI imaging and computational infrastructure needed to generate the models could also limit near-term adoption.
What Comes Next
Natalia Trayanova, senior author and Murray B. Sachs Professor of Biomedical Engineering at Johns Hopkins, described the results as “a crowning achievement in this technology that allows us to go further toward a larger clinical trial,” according to Medical Xpress. The team has already begun a separate trial applying the digital twin approach to atrial fibrillation, a far more common type of irregular heartbeat that affects millions of patients worldwide.